C-kit gene mutations in adenoid cystic carcinoma are rare

Modern Pathology

Volumn 23, Issue 6, 2010, Pages 905-906

  Moskaluk, Christopher A ^a   Frierson, Henry F ^a   El Naggar, Adel K ^b   Futreal, P Andrew ^c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; IMATINIB; STEM CELL FACTOR;

ADENOID CYSTIC CARCINOMA; ARTIFACT; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DNA DAMAGE; EXON; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; LETTER; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL;

ARTIFACTS; CARCINOMA, ADENOID CYSTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; REPRODUCIBILITY OF RESULTS; SALIVARY GLAND NEOPLASMS;

EID: 77953173040     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.61     Document Type: Letter

References (13)

1. Vila L, Liu H, Al-Quran SZ, et al. Identification of c-kit gene mutations in primary adenoid cystic carcinoma of the salivary gland. Mod Pathol 2009;22:1296-1302.
2. Holst VA, Marshall CE, Moskaluk CA, et al. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999;12: 956-960.
3. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000;154:107-111.
4. Sorensen KB, Godballe C, de Stricker K, et al. Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med 2006;35: 286-291.
5. Lin CH, Yen RF, Jeng YM, et al. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head Neck 2005;27:1022-1027.
6. Aubry MC, Heinrich MC, Molina J, et al. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer 2007;110:2507-2510.
7. Marchetti A, Felicioni L, Buttitta F, et al. Assessing EGFR mutations. N Engl J Med 2006;354:526-528.
8. Catalogue of Somatic Mutations in Cancer [database on the Internet] 2009. Wellcome Trust Sanger Institute [cited 2009]. Available from http://www.sanger.ac.uk/genetics/CGP/cosmic/.
9. Alcedo JC, Fabrega JM, Arosemena JR, et al. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases. Head Neck 2004;26:829-831.
10. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14:2717-2725.
11. Faivre S, Raymond E, Casiraghi O, et al. Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 2005;23:6271-6273.
12. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital Phase II Consortium Study. J Clin Oncol 2005;23:585-590.
13. Pfeffer MR, Talmi Y, Catane R, et al. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007;43:33-36.